Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
复制标题
DOI：
10.1371/journal.pone.0092320
复制
发表时间：
2014
期刊：
影响因子：
3.7
通讯作者：
Zhao X
中科院分区：
文献类型：
--
作者：
Dong X;Hao Y;Wei Y;Yin Q;Du J;Zhao X
晚期非小细胞肺癌（NSCLC）患者对细胞毒化疗的反应差异很大，分子标记物可能有助于确定个体患者的首选治疗方法。本回顾性研究旨在评价核糖核苷酸还原酶调节亚单位M1（RRM1）对非小细胞肺癌（NSCLC）患者铂类药物化疗疗效的预测价值。本回顾性研究纳入229例接受铂类双药化疗的晚期NSCLC患者，根据RRM1表达分析其临床结局。 在接受吉西他滨治疗的患者中，RRM1阴性肿瘤患者的疾病控制率（DCR）和无进展生存期（PFS）显著高于RRMI阳性肿瘤患者（分别为P= 0.041和P =0.01），多变量分析显示RRM1表达是独立的预后因素（P= 0.013）。 在接受多西他赛或长春瑞滨治疗的患者中未发现类似差异。在RRM1阳性患者中，多西他赛和长春瑞滨的DCR高于吉西他滨（分别为P= 0.047和P =0.047），多西他赛和长春瑞滨的PFS长于吉西他滨化疗（P= 0.012和P = 0.007）。 在RRM1阴性肿瘤患者中没有发现类似的差异。晚期NSCLC中RRM1阴性表达与吉西他滨化疗的高应答率相关。在RRM1阳性肿瘤患者中，多西他赛和长春瑞滨显示出比基于吉西他滨的治疗更高的疗效。需要更多的前瞻性研究来研究RRM1在化疗反应中的预测意义。
The response to cytotoxic chemotherapy varies greatly in patients with advanced non-small cell lung cancer (NSCLC), and molecular markers may be useful in determining a preferable therapeutic approach for individual patients. This retrospective study was performed to evaluate the predictive value of ribonucleotide reductase regulatory subunit M1 (RRM1) on the therapeutic efficacy of platinum-based chemotherapy in patients with NSCLC. Patients with advanced NSCLC who received platinum doublet chemotherapy (n = 229) were included in this retrospective study, and their clinical outcomes were analyzed according to RRM1 expression. In patients receiving gemcitabine-based therapy, the disease control rate (DCR) and progression-free survival (PFS) of patients with RRM1-negative tumors were significantly higher than in patients with RRMI-positive tumors (P = 0.041 and P = 0.01, respectively), and multivariate analysis showed that RRM1 expression was an independent prognostic factor (P = 0.013). No similar differences were found in patients receiving docetaxel- or vinorelbine-based therapy. In RRM1-positive patients, the DCRs for docetaxel and vinorelbine were higher than for gemcitabine (P = 0.047 and P = 0.047, respectively), and docetaxel and vinorelbine showed a longer PFS than gemcitabine-based chemotherapy (P = 0.012 and P = 0.007). No similar differences were found among patients with RRM1-negative tumors. Negative RRM1 expression in advanced NSCLC is associated with a higher response rate to gemcitabine-based chemotherapy. In patients with RRM1-positive tumors, docetaxel and vinorelbine showed a higher therapeutic efficacy than gemcitabine-based therapy. Additional prospective studies are needed to investigate the predictive meaning of RRM1 in the response to chemotherapy.
登录
查看更多内容
影响因子：
45.3
作者：
Scagliotti, GV;De Marinis, F;Tonato, M
通讯作者：
Tonato, M
影响因子：
45.3
作者：
Bepler, Gerold;Kusmartseva, Irina;Simon, George
通讯作者：
Simon, George
DOI：
10.1016/j.biocel.2007.05.006
发表时间：
2007-01-01
影响因子：
4
作者：
Simon, George R.;Ismail-Khan, Roohi;Bepler, Gerold
通讯作者：
Bepler, Gerold
影响因子：
6.2
作者：
Simon GR;Schell MJ;Begum M;Kim J;Chiappori A;Haura E;Antonia S;Bepler G
通讯作者：
Bepler G
影响因子：
20.4
作者：
Papadaki, Chara;Sfakianaki, Maria;Souglakos, John
通讯作者：
Souglakos, John